Inventor · disambiguated record
Christopher C. Coss
Also filed as: COSS CHRISTOPHER C · COSS CHRISTOPHER CHARLES
14 granted patents·8 pending applications·114 citations·filing 2012–2025
92Inventor score
Top patents by PatentIndex Score
22 records- 0196US10441570B2Selective androgen receptor degrader (SARD) Ligands and methods of use thereofGTX INC·Filed 2018·Granted Oct 15, 2019·12 cites·66 claims
- 0296US10093613B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2017·Granted Oct 9, 2018·9 cites·10 claims
- 0396US9814698B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Nov 14, 2017·17 cites·47 claims
- 0495US10035763B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Jul 31, 2018·15 cites·56 claims
- 0595US10017471B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Jul 10, 2018·15 cites·45 claims
- 0695US9834507B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Dec 5, 2017·13 cites·41 claims
- 0794US11273147B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofUNIV TENNESSEE RES FOUND·Filed 2019·Granted Mar 15, 2022·7 cites·30 claims
- 0891US9815776B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2016·Granted Nov 14, 2017·13 cites·56 claims
- 0989US10597354B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofGTX INC·Filed 2018·Granted Mar 24, 2020·7 cites·20 claims
- 1088US11591290B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofONCTERNAL THERAPEUTICS INC·Filed 2020·Granted Feb 28, 2023·2 cites·6 claims
- 1185US9624161B2Estrogen receptor ligands and methods of use thereofGTX INC·Filed 2014·Granted Apr 18, 2017·4 cites·15 claims
- 1277US11938105B1Methods and compositions for the treatment of cancer cachexiaOHIO STATE INNOVATION FOUNDATION·Filed 2022·Granted Mar 26, 2024·0 cites·3 claims
- 1376US2024285556A1Methods and compositions for the treatment of cancer cachexiaOHIO STATE INNOVATION FOUNDATION·Filed 2024·Application pending·0 cites
- 1474US12128026B2Selective androgen receptor degrader (SARD) ligands and methods of use thereofUNIV TENNESSEE RES FOUND·Filed 2022·Granted Oct 29, 2024·0 cites·16 claims
- 1568US2025188098A1Carborane compounds and methods of use thereofOHIO STATE INNOVATION FOUNDATION·Filed 2024·Application pending·0 cites
- 1667US11529323B2Methods and compositions for the treatment of cancer cachexiaOHIO STATE INNOVATION FOUNDATION·Filed 2018·Granted Dec 20, 2022·0 cites·2 claims
- 1763US2025281515A1Carborane compounds, carborane analogs, and methods of use thereofOHIO STATE INNOVATION FOUNDATION·Filed 2025·Application pending·0 cites
- 1861US2022040210A1Carborane compounds, carborane analogs, and methods of use thereofOHIO STATE INNOVATION FOUNDATION·Filed 2019·Application pending·0 cites
- 1950US2014057946A1Estrogen receptor ligands and methods of use thereofGtx·Filed 2013·Application pending·0 cites
- 2049US2014057985A1Estrogen receptor ligands and methods of use thereofGtx·Filed 2012·Application pending·0 cites
- 2146US2014187641A1Estrogen receptor ligands and methods of use thereofGtx·Filed 2013·Application pending·0 cites
- 2240US2013116277A1Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitorsDALTON JAMES T·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →